Cost–utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia

Imatinib mesilate (Glivec®, Novartis Pharmaceuticals) is a novel therapy for the treatment of chronic myeloid leukaemia (CML). We evaluated the cost-effectiveness of imatinib (600 mg daily) when used for the treatment of patients in advanced stages of CML (accelerated phase and blast crisis) against...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordois, A, Scuffham, P, Warren, E, Ward, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376910/
https://www.ncbi.nlm.nih.gov/pubmed/12915870
http://dx.doi.org/10.1038/sj.bjc.6601151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376910/
https://www.ncbi.nlm.nih.gov/pubmed/12915870
http://dx.doi.org/10.1038/sj.bjc.6601151

Ejemplares similares